Synopsis
Synopsis
0
JDMF
0
VMF
0
Europe
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
Annual Reports
NA
Regulatory FDF Prices
NA
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. Cefoxitin
2. Mfoxin
3. Mefoxin
4. Mefoxitin
5. Mk 306
6. Mk-306
7. Mk306
8. Sodium, Cefoxitin
1. Cefoxitin Sodium Salt
2. 33564-30-6
3. Betacef
4. Cenomycin
5. Mefoxin
6. Merxin
7. Cefoxitin (sodium)
8. Mefoxitin
9. Mls000028557
10. Chebi:3501
11. Q68050h03t
12. Smr000058809
13. Monosodium Cefoxitin
14. Sodium (6r,7s)-3-(hydroxymethyl)-7-methoxy-8-oxo-7-(2-(2-thienyl)acetamido)-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylate Carbamate (ester)
15. Cefoxil
16. Cefoxotin Sodium
17. 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic Acid, 3-(((aminocarbonyl)oxy)methyl)-7-methoxy-8-oxo-7-((2-thienylacetyl)amino)-, Sodium Salt, (6r-cis)-
18. Ncgc00183034-01
19. Mk-306
20. Unii-q68050h03t
21. Prestwick_12
22. Mefoxin In Plastic Container
23. Sodium (6r,7s)-3-((carbamoyloxy)methyl)-7-methoxy-8-oxo-7-(2-(thiophen-2-yl)acetamido)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
24. Sodium (6r,7s)-3-[(carbamoyloxy)methyl]-7-methoxy-8-oxo-7-[2-(thiophen-2-yl)acetamido]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
25. Einecs 251-574-6
26. Mefoxin (tn)
27. Cas-33564-30-6
28. Mfcd00079042
29. Mk 206
30. Cefoxitin Na
31. Cefoxitin Sodium [usan:usp:ban:jan]
32. Cefoxitin And Dextrose In Duplex Container
33. Opera_id_912
34. Cefoxitin (sodium Salt)
35. Sodium;(6r,7s)-3-(carbamoyloxymethyl)-7-methoxy-8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
36. Dsstox_cid_28921
37. Dsstox_rid_83187
38. Dsstox_gsid_48995
39. Schembl41178
40. Cefoxitin Sodium (jan/usp)
41. Mefoxin In Dextrose 5% In Plastic Container
42. Mls001076334
43. Mls002222151
44. Bidd:gt0505
45. Spectrum1502031
46. L 620388
47. Cefoxitin Sodium [jan]
48. Cefoxitin Sodium [usan]
49. Cefoxitin Sodium [vandf]
50. Chembl1200530
51. Dtxsid8048995
52. Cefoxitin For Peak Identification
53. Hms501m18
54. Cefoxitin Sodium [mart.]
55. Cefoxitin Sodium [who-dd]
56. Hms1570h05
57. Hms1921f14
58. Hms2092p11
59. Hms2097h05
60. Hms2232e15
61. Hms3259k10
62. Hms3714h05
63. Mefoxin In Sodium Chloride 0.9% In Plastic Container
64. Cefoxitin Sodium Salt [mi]
65. Bcp12069
66. Hy-b1117
67. Tox21_113485
68. Ccg-39693
69. Akos024464829
70. Cefoxitin Sodium [orange Book]
71. Ac-1303
72. Cefoxitin Sodium [usp Impurity]
73. Cs-4716
74. Nc00556
75. Cefoxitin Sodium [usp Monograph]
76. As-56725
77. Sodium (6r-cis)-3-((carbamoyloxy)methyl)-7-methoxy-8-oxo-7-(2-thienylacetamido)-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylate
78. C3602
79. C-2480
80. C08106
81. D00913
82. A821839
83. (r)-4-isopropyl-5,5-diphenyl-2-oxazolidinone
84. Q27106110
85. Cefoxitin Sodium Salt, Antibiotic For Culture Media Use Only
86. (6r,7s)-3-[[(aminocarbonyl)oxy]methyl]-7-methoxy-8-oxo-7-[(2-thienylacetyl)amino]-5-thia-1-azabicyclo[420]oct-2-ene-2-carboxylic Acid Sodium Salt
87. 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic Acid, 3-(((aminocarbonyl)oxy)methyl)-7-methoxy-8-oxo-7-((2-thienylacetyl)amino)-, Monosodium Salt, (6r-cis)-
88. Sodium (6r,7s)-3-(carbamoyloxymethyl)-7-methoxy-8-oxo-7-(2-(thiophen-2-yl)acetamido)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
Molecular Weight | 449.4 g/mol |
---|---|
Molecular Formula | C16H16N3NaO7S2 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 9 |
Rotatable Bond Count | 8 |
Exact Mass | 449.03273649 g/mol |
Monoisotopic Mass | 449.03273649 g/mol |
Topological Polar Surface Area | 205 Ų |
Heavy Atom Count | 29 |
Formal Charge | 0 |
Complexity | 750 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 2 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 4 | |
---|---|
Drug Name | Cefoxitin and dextrose in duplex container |
Active Ingredient | Cefoxitin sodium |
Dosage Form | Injectable |
Route | Injection |
Strength | eq 2gm base/vial; eq 1gm base/vial |
Market Status | Prescription |
Company | B Braun |
2 of 4 | |
---|---|
Drug Name | Mefoxin in plastic container |
Active Ingredient | Cefoxitin sodium |
Dosage Form | Injectable |
Route | Injection |
Strength | eq 40mg base/ml; eq 20mg base/ml |
Market Status | Prescription |
Company | Mylan Institutional |
3 of 4 | |
---|---|
Drug Name | Cefoxitin and dextrose in duplex container |
Active Ingredient | Cefoxitin sodium |
Dosage Form | Injectable |
Route | Injection |
Strength | eq 2gm base/vial; eq 1gm base/vial |
Market Status | Prescription |
Company | B Braun |
4 of 4 | |
---|---|
Drug Name | Mefoxin in plastic container |
Active Ingredient | Cefoxitin sodium |
Dosage Form | Injectable |
Route | Injection |
Strength | eq 40mg base/ml; eq 20mg base/ml |
Market Status | Prescription |
Company | Mylan Institutional |
Anti-Bacterial Agents
Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
85
PharmaCompass offers a list of Cefoxitin Sodium API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Cefoxitin Sodium manufacturer or Cefoxitin Sodium supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Cefoxitin Sodium manufacturer or Cefoxitin Sodium supplier.
PharmaCompass also assists you with knowing the Cefoxitin Sodium API Price utilized in the formulation of products. Cefoxitin Sodium API Price is not always fixed or binding as the Cefoxitin Sodium Price is obtained through a variety of data sources. The Cefoxitin Sodium Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A DSSTox_CID_28921 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of DSSTox_CID_28921, including repackagers and relabelers. The FDA regulates DSSTox_CID_28921 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. DSSTox_CID_28921 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of DSSTox_CID_28921 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A DSSTox_CID_28921 supplier is an individual or a company that provides DSSTox_CID_28921 active pharmaceutical ingredient (API) or DSSTox_CID_28921 finished formulations upon request. The DSSTox_CID_28921 suppliers may include DSSTox_CID_28921 API manufacturers, exporters, distributors and traders.
click here to find a list of DSSTox_CID_28921 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A DSSTox_CID_28921 DMF (Drug Master File) is a document detailing the whole manufacturing process of DSSTox_CID_28921 active pharmaceutical ingredient (API) in detail. Different forms of DSSTox_CID_28921 DMFs exist exist since differing nations have different regulations, such as DSSTox_CID_28921 USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A DSSTox_CID_28921 DMF submitted to regulatory agencies in the US is known as a USDMF. DSSTox_CID_28921 USDMF includes data on DSSTox_CID_28921's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The DSSTox_CID_28921 USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of DSSTox_CID_28921 suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a DSSTox_CID_28921 Drug Master File in Korea (DSSTox_CID_28921 KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of DSSTox_CID_28921. The MFDS reviews the DSSTox_CID_28921 KDMF as part of the drug registration process and uses the information provided in the DSSTox_CID_28921 KDMF to evaluate the safety and efficacy of the drug.
After submitting a DSSTox_CID_28921 KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their DSSTox_CID_28921 API can apply through the Korea Drug Master File (KDMF).
click here to find a list of DSSTox_CID_28921 suppliers with KDMF on PharmaCompass.
A DSSTox_CID_28921 CEP of the European Pharmacopoeia monograph is often referred to as a DSSTox_CID_28921 Certificate of Suitability (COS). The purpose of a DSSTox_CID_28921 CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of DSSTox_CID_28921 EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of DSSTox_CID_28921 to their clients by showing that a DSSTox_CID_28921 CEP has been issued for it. The manufacturer submits a DSSTox_CID_28921 CEP (COS) as part of the market authorization procedure, and it takes on the role of a DSSTox_CID_28921 CEP holder for the record. Additionally, the data presented in the DSSTox_CID_28921 CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the DSSTox_CID_28921 DMF.
A DSSTox_CID_28921 CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. DSSTox_CID_28921 CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of DSSTox_CID_28921 suppliers with CEP (COS) on PharmaCompass.
A DSSTox_CID_28921 written confirmation (DSSTox_CID_28921 WC) is an official document issued by a regulatory agency to a DSSTox_CID_28921 manufacturer, verifying that the manufacturing facility of a DSSTox_CID_28921 active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting DSSTox_CID_28921 APIs or DSSTox_CID_28921 finished pharmaceutical products to another nation, regulatory agencies frequently require a DSSTox_CID_28921 WC (written confirmation) as part of the regulatory process.
click here to find a list of DSSTox_CID_28921 suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing DSSTox_CID_28921 as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for DSSTox_CID_28921 API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture DSSTox_CID_28921 as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain DSSTox_CID_28921 and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a DSSTox_CID_28921 NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of DSSTox_CID_28921 suppliers with NDC on PharmaCompass.
DSSTox_CID_28921 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of DSSTox_CID_28921 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right DSSTox_CID_28921 GMP manufacturer or DSSTox_CID_28921 GMP API supplier for your needs.
A DSSTox_CID_28921 CoA (Certificate of Analysis) is a formal document that attests to DSSTox_CID_28921's compliance with DSSTox_CID_28921 specifications and serves as a tool for batch-level quality control.
DSSTox_CID_28921 CoA mostly includes findings from lab analyses of a specific batch. For each DSSTox_CID_28921 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
DSSTox_CID_28921 may be tested according to a variety of international standards, such as European Pharmacopoeia (DSSTox_CID_28921 EP), DSSTox_CID_28921 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (DSSTox_CID_28921 USP).